Genzyme's surgical mesh gets US clearance:
This article was originally published in Clinica
Genzyme Surgical Products has received 510(k) clearance from the US FDA to market its Sepramesh Biosurgical Composite for use in hernia repair procedures. The surgical mesh is designed to be sutured in place along the abdominal wall providing support and strength to the hernia repair. Sepramesh contains a bioresorbable barrier that separates the mesh from underlying tissue and organ surfaces to minimise attachment to the mesh. This offers significant advantages over traditional mesh products, the Cambridge, Massachusetts-based company said.
You may also be interested in...
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 9)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this ninth installment of a 10-part series, the experts talk about the importance of maintaining a record of the inspection.
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.